

CURE ALZHEIMER'S FUND

Alzheimer's disease is one of the most challenging diseases of our time. 6 million people in the United States – and 50 million worldwide – have been diagnosed with the disease, and it is estimated that these counts are under-represented – that there may be 4X as many people who actually have the disease, with the majority not diagnosed. The disease is more than just an inconvenient loss of memory: it results in the slow, degradation of the structure of the brain with eventual loss of many motor and other human functions. In the past 20 years, the death rate in the United States has increase 175%; Alzheimer's disease is always fatal.

Cure Alzheimer's Fund was started in September of 2004 by Jeff and Jacqui Morby and soon joined by Henry McCance and Phyllis Rappaport as the founders. Originally started as the Alzheimer's Disease Research Foundation, it's d/b/a Cure Alzheimer's Fund (CureAlz) was established and incorporated as a 501c3 public charity. The purpose of the organization is reflected in its mission statement: to fund research with the highest probability to slow, stop or reverse Alzheimer's disease.

CureAlz takes a venture philanthropy approach to its mission.

- CureAlz takes no interest in the intellectual property of the research it funds.
- Instead of the traditional approach of investing in research that builds in upon existing knowledge with small, incremental investigations, CureAlz invests in research that is fundamental to understanding the causes of the disease. Researchers are encouraged to think big and unconventional ideas are often funded, leading to new and significant findings
- 100% of all donations go to support research into Alzheimer's disease. Our Board of Directors and Trustees pay for all overhead expenses.
- The researchers who receive grants from CureAlz are required to collaborate and share their results to provide for advancement in scientific discovery.
- Research results of the funding are made available to all scientists in the field for their advancement of knowledge and to fuel progress by all.

Through 2022, 675 research grants have been provided by CureAlz to 250 scientists throughout the world, representing \$160 million in funding of research into Alzheimer's disease.

Genetics has a key role in Alzheimer's disease and this role is better understood due to the work of the researchers involved in the Alzheimer's Genome Project. More than 100 genes have been identified as having a role with the disease (some are protective against the disease – others are deleterious) and a key

gene, APOE, is a focus of one of the CureAlz consortia with many researchers from various institutions working together to investigate causes and effects.